Description

Celadon Pharmaceuticals Plc functions as a drug development company, concentrating on the discovery, production, and distribution of cannabinoid compounds for certified medical uses. The firm's primary activity involves the indoor, hydroponic cultivation of THC cannabis, which is then incorporated into medicinal products targeting chronic pain. Furthermore, Celadon intends to broaden its research into cannabinoids, exploring their therapeutic applications not only for persistent pain but also for conditions such as autism and multiple sclerosis. Established in 2018, the company maintains its headquarters in London, United Kingdom.